Which manufacturer does Seleniso come from?

Selinexor (Selinexor), this innovative targeted therapy drug, is developed and produced by the company Karyopharm Therapeutics. Karyopharm, an innovative company focusing on the field of biopharmaceuticals, has been committed to the research, development and commercialization of drugs for major diseases such as cancer and immune diseases since its establishment in 2008.

Located in Waltham, Massachusetts, USAKaryopharm, with its unique R&D perspective, focuses on developing drugs that can interfere with the nuclear export pathway. This type of drug can accurately target tumor cells and bring new hope for cancer treatment. Among them, Seliniso is its outstanding representative. It effectively interferes with the normal operation of cancer cells by inhibiting the function of Exportin 1 (XPO1), thus blocking the growth and spread of tumors and providing new treatment options for patients with hematological malignancies such as multiple myeloma.

Karyopharm Therapeutics is not only responsible for the research and development of Seleniso, but also personally produces it. At the same time, in order to cover market needs more broadly, it has established close cooperative relationships with many drug distributors and pharmaceutical companies around the world. The drug's original research and production facilities are located in the United States. Karyopharm will work with appropriate partners based on local market needs to jointly promote the production and distribution of selinesol.

In China, Seleniso was also able to appear on the market, thanks toKaryopharm's cooperation with local pharmaceutical companies. Specific sales and distribution channels will be jointly planned by Karyopharm and its partners to ensure that the drugs can reach patients smoothly. Since its launch, selinesol has attracted widespread attention in the field of relapsed or refractory multiple myeloma due to its remarkable efficacy. Although it is expensive as an imported drug, with the gradual coverage of medical insurance policies, the financial burden on patients has also been reduced.

xa0

Reference materials:

National Medical Products Administration (NMPA) official website. Seleniso approval information:https://www.nmpa.gov.cn